



Update to December 2018 Appendix 4C:

Revised R&D Tax Incentive Claim

Brisbane 4th February 2019: Factor Therapeutics (ASX:FTT, the “Company”) advises that it has now received results of the full review of the Company’s R&D activities and expenditure for the financial year ended 31 December 2018. In the year, approximately \$5.7 million of eligible R&D expenditure was incurred, primarily in relation to the Phase 2 clinical trial conducted in the US for which the Company has received an Advanced Overseas Finding. As a result, a rebate of up to approximately \$2.5 million may be received by the Company under the federal government’s Research and Development (R&D) Tax Incentive Scheme. Receipt of these funds, expected in May 2019, remains subject to the usual submission activities and processes.

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson

Factor Therapeutics Limited

r.wilson@factor-therapeutics.com